Fibroblast growth factor 23 is induced by an activated renin-angiotensin-aldosterone system in cardiac myocytes and promotes the pro-fibrotic crosstalk between cardiac myocytes and fibroblasts Conclusions. Our data demonstrate that activated RAAS induces FGF23 expression in cardiac myocytes and thereby stimulates a pro-fibrotic crosstalk between cardiac myocytes and fibroblasts, which may contribute to myocardial fibrosis in CKD.
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I N T R O D U C T I O N
Cardiac fibrosis and left ventricular hypertrophy (LVH) are common features of cardiomyopathies that contribute to the excessive cardiovascular mortality in patients with and without chronic kidney disease (CKD), and both pathological cardiac remodeling characteristics are highly correlated [1, 2] . Increased synthesis of extracellular matrix (ECM) proteins in myofibroblasts, in parallel with or without ECM degradation regulated by matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs), results in excessive cardiac fibrosis and enhanced accumulation of fibrillar collagens type I and type III (COL1A2, COL3A1) in the intramuscular space [3] .
The intense crosstalk between cardiac myocytes and fibroblasts is mediated by locally secreted growth factors, cytokines and plasma hormones [3, 4] , of which, among others, activation of the renin-angiotensin-aldosterone system (RAAS) and its downstream target pathways have been shown to stimulate the progression of cardiac hypertrophy, remodeling, collagen synthesis and fibrosis in a paracrine/autocrine manner [5, 6] . Angiotensinogen (AGT) as the first component of RAAS, encoded by the gene AGT, is cleaved by the enzyme renin, resulting in angiotensin I, which is further cleaved by angiotensin-converting enzyme (ACE) into AngII. AngII directly induces aldosterone [7] , COL1A2 and COL3A1 [8, 9] and transforming growth factor (TGF)-b [2, 6, 10] . The latter exists in three isoforms, encoded by the genes TGFB1, TGFB2 and TGFB3, whereas TGF-b1 is the predominant form in the heart regulating cell proliferation, differentiation, apoptosis and ECM production [3] . After binding of TGF-b to TGF-b receptors type 1 (TGFBR1) and type 2 (TGFBR2) on cardiac myocytes and fibroblasts, the activated complex phosphorylates Smad2 and Smad3, which associate with Smad4, translocate into the nucleus and act as transcription factors to induce fibrosis-related genes, including connective tissue growth factor (CTGF) and collagens [2, 10, 11] . Released by cardiac fibroblasts and myocytes, CTGF promotes both cardiac fibrosis and hypertrophy [12] . In addition, AngII and TGF-b induce endothelin-1 (ET-1), encoded by the gene EDN1, a paracrine growth factor linked to certain cardiac, vascular and renal diseases promoting fibroblast activation and resulting in cardiac fibrosis and hypertrophy [13] .
In uremic cardiomyopathy, the bone-derived phosphaturic hormone fibroblast growth factor 23 (FGF23) progressively rises with declining kidney function and is up to 1000-fold elevated in patients with end-stage CKD, while in parallel the renal expression of its co-receptor klotho declines [14] . Both dysregulations independently associate with the presence of LVH and cardiovascular mortality in CKD [15] [16] [17] [18] . We recently showed that FGF23 directly stimulates cardiac hypertrophy independent of klotho via activation of the FGF receptor 4 (FGFR4)/calcineurin/nuclear factor of activated T cell (NFAT) signaling pathway in vitro and in vivo [19, 20] . Furthermore, we and others demonstrated that FGF23 is expressed by cardiac myocytes in humans and rodents [17, [21] [22] [23] and that cardiac FGF23 is upregulated in experimental uremia as well as in patients with end-stage CKD and associates with the development of LVH [17, 21] . Recent studies showed that myocardial and circulating levels of FGF23 are also enhanced in patients with dilated cardiomyopathy [22] and acute and chronic heart failure [24] [25] [26] [27] [28] despite normal renal function. However, the impact of FGF23 on cardiac fibrosis is largely elusive.
Since RAAS activation is thought to enhance bone-derived FGF23 in CKD [29] , we wanted to determine the role of cardiac RAAS and FGF23 in the development of cardiac fibrosis by using myocardial autopsy samples of patients with end-stage CKD and in vitro studies in cardiac myocytes and fibroblasts.
M A T E R I A L S A N D M E T H O D S

Human study population and ethical standards
This retrospective case-control study includes formalinfixed paraffin-embedded (FFPE) myocardial autopsy samples of the left ventricle from 24 patients with childhood-onset endstage CKD, either on dialysis treatment (n ¼ 17) or with a functioning renal allograft (n ¼ 7), with 24 age-and sex-matched non-CKD patients serving as controls. The study was performed in compliance with the Declaration of Helsinki and its later amendments and was approved by the Ethical Committee of Hannover Medical School . Patients and controls underwent detailed autopsy and human myocardial autopsy samples were investigated for induction of cardiac fibrosis. Controls with heart or kidney disorders were excluded. Detailed clinical characteristics of patients and controls were published previously [17] .
Histological staining and quantification of interstitial cardiac fibrosis
Human FFPE myocardial tissue sections were stained with picrosirius red as previously published and quantified for myocardial fibrosis [20] . In brief, 4-mm-thick sections were deparaffinized, incubated with picrosirius red solution and analysed by bright field and polarized microcopy. Twenty images per slide (no pericardium, no fatty tissue or excessive number of coronary vessels) were taken using a BZ-9000 microscope (Keyence, Osaka, Japan) with a 20Â objective. For polarized light microscopy, two polarization filters were used in a rectangular orientation, positioned before and after the sample. Quantification of interstitial myocardial fibrosis was performed using Keyence Analyzer software and the collagen content was determined as the fold increase of picrosirius redpositive area per field of view from a patient in relation to its respective age-and sex-matched control.
Impact of FGF23 on cardiac fibrosis
Isolation, culture and treatment of neonatal rat cardiac fibroblasts and neonatal rat ventricular myocytes Neonatal rat cardiac fibroblasts (NRCFs) and neonatal rat ventricular myocytes (NRVMs) were isolated from Sprague Dawley rats using a standard protocol as described previously [30] . NRCFs were used from passages one to three. The 5 Â 10 5 NRCFs were seeded on six-well plates using Dulbecco's modified Eagle's medium (DMEM) with 10% foetal bovine serum (FBS) and cultured until the growth density reached 80-90%. The 2 Â 10 6 NRVMs were seeded on 6-cm culture dishes precoated with 1% gelatin using DMEM with 20% M199, 5% FBS and 10% horse serum for 24 h. Prior to stimulation with recombinant human FGF23 (100 ng/mL), TGF-b (1 ng/mL), angiotensin II (100 nM), aldosterone (100 nM) or vehicle for different time points as indicated, NRCFs and NRVMs were starved in DMEM with 1% FBS or M199, respectively, for 24 h.
RNA isolation from human myocardial autopsy samples and performance of fibrosis-related gene expression profiling by quantitative real-time polymerase chain reaction (PCR) analysis Total RNA from FFPE human myocardial autopsy samples was isolated using the RNeasy FFPE Kit (Qiagen, Venlo, The Netherlands) and 500 mg RNA was transcribed into cDNA using the RT 2 PreAMP cDNA Synthesis Kit (Qiagen). Gene expression analyses of 11 patients on dialysis treatment and their matched controls were performed on 384-well plates using the human fibrosis RT 2 Profiler PCR Array (Qiagen, Hilden, Germany) according to the manufacturer's protocol, followed by quantitative real-time PCR on an 7900HT Fast Real-Time PCR System (Applied Biosystems, Foster City, CA, USA). Cardiac FGF23 and FGFR4 messenger RNA (mRNA) levels were determined as described previously [17] . Within the fibrosis array, the housekeeping genes beta-2-microglobulin (B2M), hypoxanthine phosphoribosyltransferase 1 (HPRT1), ribosomal protein L13a (RPL13A), glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and bactin (ACTB) were according to the manufacturer's protocol. Relative gene expression values in patients compared with respective controls were calculated according to the 2 ÀDDC T method [31] adjusted for the same threshold cycle (C T ) and baseline settings.
RNA isolation from NRCFs and NRVMs and quantitative real-time PCR analysis
The RNeasy Mini Kit was used for total RNA isolation from NRCFs and NRVMs and 500 mg of RNA was transcribed into cDNA using the QuantiTect Reverse Transcription Kit (Qiagen, Hilden, Germany). Quantitative real-time PCR was performed in triplicate using the QuantiFAST SYBR Green PCR Kit including ROX dye (Qiagen, Hilden, Germany). Oligonucleotide sequences are available in the supplementary material (Supplementary data, Table S1 ). In addition, RNA from NRCFs and NRVMs was transcribed into cDNA using the RT 2 PreAMP cDNA Synthesis Kit, followed by further gene expression profiling using the rat fibrosis RT 2 Profiler PCR Array System (both from Qiagen) according to the manufacturer's protocol. Housekeeping genes included in the array were ribosomal protein large P1 (RPLP1), HPRT1, RPL13A, lactate dehydrogenase A (LDHA) and ACTB. Relative gene expression values in respective cell treatments were compared with vehicle-stimulated cells and calculated according to the 2 ÀDDC T method [31] adjusted for the same C T and baseline settings.
Proliferation and migration of NRCFs
Proliferation of NRCFs was analysed by the CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, Madison, WI, USA) according to the manufacturer's protocol. In brief, 5000 cells per well were seeded into 96-well flat-bottom cell culture plates and allowed to attach overnight. After starvation of NRCFs overnight followed by treatment with recombinant human FGF23, TGF-b or vehicle in quadruplicate for 24 h, 20 mL/well CellTiter 96 AQueous One Solution reagent was added. Absorbance at 490 nm was recorded after 4 h and FGF23-and TGF-b-stimulated proliferation of NRCFs was quantified in the percent age of vehicle-treated control cells.
Cardiac fibroblast migration was determined using two-well cell culture inserts (ibidi, Martinsried, Germany) with a gap size of 500 6 50 mm in eight-well glass bottom microslides. In total, 40 000 cells/0.22 mm 2 were plated. After attachment and starvation, cell culture inserts were carefully removed followed by stimulation of NRCFs with recombinant human FGF23, TGF-b or vehicle. Cell migration was analysed immediately by live cell imaging using an Axio Observer Z1 microscope with a 20Â objective (Objective LD Plan-Neofluar 20Â/0.4 Corr Ph2; Carl Zeiss, Goettingen, Germany.) at the start and after 8, 24, 32 and 48 h. Phase-contrast images were analyzed using the MRI Wound Healing Tool for ImageJ [32] on ImageJ version 2.0.0-rc59/1.51k [33] . A variance-based method was used either directly on phase-contrast images or after edge detection. Migration was quantified as the percent of gap closure compared with gap size at the start.
S T A T I S T I C A L A N A L Y S I S
All data are presented as mean 6 standard deviation (SD) or median [interquartile range (IQR)] unless otherwise indicated. After testing for Gaussian distribution using the KolmogorovSmirnov test, comparisons between patients and controls were done by paired t-test or Wilcoxon matched-pairs signed-rank test using GraphPad Prism 6.0 (GraphPad Software, La Jolla, CA, USA). Two-sided Pearson's or Spearman's rank correlation was performed for the association between cardiac fibrosis and clinical parameters of patients and stepwise multiple linear regression analyses were conducted for variables associated with P < 0.1 on univariate analysis (Supplementary data, Table  S2 ) using SPSS software version 24 (IBM, Armonk, NY, USA). For analyses of NRCF and NRVM results, data from at least five independent cell isolations, each containing at least three technical replicates per group, were used for the comparison of treated cells with vehicle-treated control cells using a two-sided unpaired t-test. One-way analysis of variance followed by a Bonferroni or Kruskal-Wallis test followed by Dunn's post hoc test were performed in case of more than two comparisons. P <0.05 was considered statistically significant.
R E S U L T S Enhanced cardiac fibrosis correlates with dialysis vintage and klotho deficiency in CKD patients
The majority of patients were on dialysis (71%) at the time of death. When compared with those with a functioning renal transplant, dialysis patients spent longer cumulative time on dialysis and presented with higher time-averaged serum phosphate and parathyroid hormone (PTH) levels, blood pressure (BP) and intake of active vitamin D (calcitriol). However, the differences only reached statistical significance for dialysis vintage and phosphate levels ( Table 1 ). As we have previously shown, expression of FGF23 [17] and FGFR4 [20] were specifically localized in cardiac myocytes and both were upregulated in the dialysis cohort compared with controls (Table 1) , whereas klotho as a co-factor of FGF23 was not expressed in human myocardial tissue at the mRNA level [17] . Interestingly, klotho protein was clearly detected by immunoblot analysis of snap-frozen human heart lysates, indicating that klotho protein in the heart might come from the circulation and can only be the soluble form. Detected by immunohistochemical staining of FFPE myocardial autopsy samples using anti-klotho antibody, the percentage of klotho-positive area was significantly decreased in dialysis patients compared with matched controls (Table 1 ) [17] . Interstitial cardiac fibrosis was increased in dialysis patients but not in those with a functioning renal allograft ( Figure 1A ). As cardiac fibrosis was almost exclusively limited to dialysis patients, we next performed subgroup analyses demonstrating that cardiac fibrosis positively correlated with dialysis vintage and negatively with the percentage of klotho-positive area in heart tissue of dialysis patients ( Figure 1B ). In contrast, cardiac FGF23 and FGFR4 expression and clinical parameters, including time-averaged serum phosphate and PTH levels, BP, the use of ACE inhibitors or calcitriol intake, were not significant correlates (Supplementary data, Table S2 ).
AGT and AngII-driven pathways, including collagen synthesis, TGF-b activation and ET-1 expression, are upregulated in heart tissue of dialysis patients Next, we investigated the expression of genes regulating fibrotic processes in myocardial tissue of 11 dialysis patients compared with matched controls (Supplementary data, Table S3 ) using human fibrosis profiler PCR arrays including 84 different genes. Within the patient cohort used for gene array analyses, the degree of cardiac fibrosis was 2.39-fold (IQR 0.68-6.91) higher when compared with matched controls. Sixty-three genes were clearly detected, with 30 genes being significantly regulated in the dialysis cohort (Supplementary data, Table S4 ). AGT, the first component of the RAAS, was significantly upregulated in the heart tissue of dialysis patients compared with controls ( Figure 2A ). The expression of COL1A2 and COL3A1 was also enhanced, although this did not reach statistical significance, and MMP9 as well as TIMP1 and TIMP4 responsible for collagen remodeling were significantly increased ( Figure 2B ). Regarding the TGF-b/TGF-b receptor/Smad complexes, TGFB1, TGFBR1 and TGFBR2 as well as SMAD3 were significantly increased in the myocardial tissue of dialysis patients, while the expression of SMAD7, which physiologically impedes Smad2/Smad3 phosphorylation, was greatly decreased ( Figure 2C ). The downstream target CTGF was significantly induced compared with controls and EDN1 was upregulated in the heart of dialysis patients as well ( Figure 2D) . Interestingly, the induction of AGT positively Impact of FGF23 on cardiac fibrosis correlated with the amount of cardiac fibrosis and the reduced amount of klotho-positive area in heart tissue of dialysis patients was associated with the induction of TGFB1 and TGFBR1 expression ( Figure 2E ). In contrast, enhanced cardiac expression of FGF23 and FGFR4 was not associated with the induction of any fibrosis-related genes. By stepwise multiple linear regression analysis, cardiac fibrosis was shown to be independently associated with dialysis vintage and the amount of klotho in the cardiac tissue of dialysis patients (cumulative R 2 ¼0.839; P ¼ 0.004).
FGF23 stimulates collagen remodeling and promotes the induction of pro-fibrotic TGF-b receptor/Smad complexes in cultured cardiac fibroblasts
In contrast to cardiac myocytes, fibroblasts did not express FGF23 [17] , suggesting that FGF23 is secreted exclusively by cardiac myocytes in the heart and thus may contribute to cardiac fibrosis only via enhanced circulating levels and/or paracrine mechanisms. Therefore we next performed fibrosis gene array analyses in FGF23 and vehicle-stimulated NRCFs. Seventy-five of 84 different genes were clearly detected in NRCFs independent of stimulation, from which 27 genes were significantly upregulated in FGF23-treated NRCFs when compared with controls (Supplementary data, Table S5 ). It was shown that FGF23 is directly involved in activation of the RAAS by inhibiting ACE2 and consequently blocking the degradation of AngII [7] , but Agt, the initial gene involved in the RAAS, was not consistently induced by FGF23 in NRCFs ( Figure 3A) . In contrast, genes responsible for collagen biosynthesis, i.e. COL3A1 and collagen binding protein 1 (Serpinh1), were significantly upregulated by FGF23, and collagen remodeling genes, such as Mmp9 as well as Timp2 and Timp3, were further induced ( Figure 3A) . Although Tgfb1 was not induced by FGF23 treatment, the TGF-b receptor (Tgfbr1, Tgfbr2) and Smad (Smad2, Smad 3, Smad4) complex was activated in this setting ( Figure 3B ). Among AngII targets, FGF23 significantly stimulated EDN1 ( Figure 3C ) and vascular endothelial growth factor A (VEGFA), which induces proliferation and migration of vascular endothelial cells in NRCFs (Supplementary data, Table S5 ). Furthermore, FGF23 induced genes for AKT serine/threonine kinase 1 (Akt1), which is responsible for FGF-induced cell motility and survival [34] , four integrin isoforms (Itga1, Itgb1, Itgb5, Itgb8) and thrombospondin 1 and 2 (Thbs1, Thbs2), which promote cell-to-cell and cellto-matrix interaction, and genes involved in inflammation, such as macrophage inflammatory protein 1a (Ccl3), interleukin 13 (Il13) and tumor necrosis factor (Tnf) (Supplementary data, Table S5 ). 
FGF23 promotes proliferation and migration of isolated cardiac fibroblasts
Cardiac fibroblasts respond to pro-fibrotic factors with increased cell proliferation and migration, resulting in enhanced myocardial fibrosis. In order to evaluate the impact of FGF23 on this functional outcome parameter we next stimulated NRCFs with either recombinant FGF23 or TGF-b as a positive control and quantified the cell proliferation in comparison with vehicle-treated cells. FGF23 significantly promotes the proliferation of cardiac fibroblasts ( Figure 4A ). However, the proliferative properties of FGF23 were lower compared with TGF-b. By performing single-cell migration assays, FGF23 significantly enhanced the migratory capacity of cardiac fibroblasts after 32 and 48 h compared with vehicle-treated NRCFs 2 PCR Profiler Array analysis of 11 dialysis versus matched control patient heart tissue samples of the left ventricle showed significant induction of AGT. Mean 6 SEM; **P < 0.01 in Student t-test. (B) Myocardial mRNA profiling did not reveal significant differences (ns) in the expression of collagen I (COL1A2) and collagen III (COL3A1) in patients on dialysis treatment, although collagen remodeling enzyme matrix metallopeptidase-9 (MMP9) and tissue inhibitor of MMP1 (TIMP1) and MMP4 (TIMP4) showed significant inductions when compared with control heart tissue. Mean 6 SEM; **P < 0.01, ***P < 0.001, ****P < 0.0001 in Student t-test, respectively. (C) Transforming growth factor b1 (TGFB1), TGF-b receptor 1 (TGFBR1) and 2 (TGFBR2) as well as SMAD3 were significantly increased in myocardial tissue of dialysis patients and SMAD7 was decreased when compared with respective controls demonstrated by PCR array analysis. Mean 6 SEM; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 in Student t-test, respectively. (D) The mRNA expression of downstream targets of the TGF-b receptor/Smad complexes CTGF and endothelin 1 (EDN1) was significantly upregulated in heart tissue of dialysis patients compared with controls. Mean 6 SEM; **P < 0.01, ****P < 0.0001 in Student t-test, respectively. (E) Pearson correlation revealed a strong association of log-transformed fold-change cardiac fibrosis with AGT expression levels in myocardial tissue of dialysis patients (left panel). Immunohistochemical staining of myocardial sections from patients on dialysis with anti-klotho antibody followed by quantification of klotho protein in percentage of positive stained area showed negative correlation with TGFB1 (middle panel) and TGFBR1 (right panel) mRNA levels. White dots, age-and sex-matched controls; gray dots, dialysis patients.
Impact of FGF23 on cardiac fibrosis ( Figure 4B and C). Fibroblasts treated with TGF-b as a positive control showed a significant increased migrated area after 24 h. After 48 h, TGF-b induced the migration of NRCFs to a similar extent as FGF23.
FGF23 induces pro-fibrotic and pro-hypertrophic growth factors, promotes extracellular matrix remodeling and stimulates inflammatory processes in cardiac myocytes in vitro
Several different cell types are implicated in fibrotic cardiac remodeling processes, either directly by producing ECM proteins or indirectly by secreting pro-fibrotic factors [35] . As FGF23 is expressed by cardiac myocytes [17, 22] , we next stimulated NRVMs with recombinant FGF23 followed by fibrosis gene array analyses and compared these with vehicletreated myocytes. Eighty-four genes were clearly expressed in cardiac myocytes, of which 27 were significantly regulated by FGF23 treatment (Supplementary data, Table S6 ). FGF23 induced Agt, COL1A2, Serpinh1 and lysyl oxidase encoded by the gene Lox, which is involved in collagen biosynthesis and an important biomarker of mechanistic fibrotic pathways in the heart [35] (Figure 5A ). In contrast to cardiac fibroblasts, Ctgf and Edn1 were consistently upregulated by FGF23 in myocytes ( Figure 5B). Moreover, FGF23 stimulated genes for the ECM remodeling enzymes plasminogen (Plg), a1 trypsin inhibitor (Serpina1) and plasminogen activator inhibitor 1 (PAI-1) encoded by Serpine1, as well as Mmp9 ( Figure 5C ). Interestingly, Mmp3, which is known to bind to collagen fibrils and is inhibited by PAI-I, was significantly repressed by FGF23 in cardiac myocytes, and the collagenase Mmp8, which is important in myocardial remodeling, was also downregulated ( Figure 5C ). However, Tgfb1, which stimulates MMP9 synthesis and inhibits MMP3, and its related TGF-b receptor/Smad complexes were not altered by FGF23 treatment ( Figure 5D ). Nevertheless, FGF23 induced the latent TGF-b binding protein 1 encoded by Ltbp1, which controls the activity of TGF-b1, and the glycoproteins Thbs1 and 2, while the small leucine-rich proteoglycan decorin (Dcn), known to negatively regulate fibrosis, was inhibited by FGF23 in cardiac myocytes ( Figure 5D ). Akt1 and the anti-apoptotic gene Bcl2 were induced by FGF23 treatment (Supplementary data, Table S6 ), suggesting the induction of pro-survival pathways. Importantly, FGF23 stimulation strongly impacts on inflammatory genes, demonstrated by the induction of Il13 and its receptor subunit a2 (Il13ra2), as well as eotaxin (Ccl11), which is known to be activated through Il13 receptor activation of the JAK/STAT6 pathway, and Tnf Although collagen I (COL1A2) was unchanged, collagen III (COL3A1) and collagen binding protein 1 (Serpinh1), both responsible for collagen biosynthesis, were significantly upregulated after NRCF stimulation with FGF23 when compared with vehicle-treated cells, and collagen remodeling genes, matrix metallopeptidase-9 (Mmp9), tissue inhibitor of MMP 2 (Timp2) and 3 (Timp3) were significantly induced by FGF23 as well. Mean 6 SEM; *P < 0.05, **P < 0.01 in Student t test, respectively; n ¼ 4 independent isolations of NRCF. ns, not significant. (B) Transforming growth factor b receptor 1 (Tgfbr1) and 2 (Tgfbr2), as well as Smad2, Smad3 and Smad4 mRNA expression was significantly enhanced in NRCFs treated with FGF23 when compared with vehicle-stimulated cells, while TGF-b1 (Tgfb1) levels remained unchanged. Mean 6 SEM; *P < 0.05, ***P < 0.001 in Student t-test, respectively; n ¼ 4 independent isolations of NRCFs. ns, not significant. (C) Endothelin 1 (Edn1) was significantly altered upon stimulation of NRCFs with FGF23, while FGF23 treatment did not affect Ctgf gene expression in NRCFs. Mean 6 SEM; *P < 0.05 in Student t-test; n ¼ 4 independent isolations of NRCFs. ns, not significant. White dots, vehicle-treated NRCFs; gray dots, FGF23-stimulated NRCFs.
( Figure 5E ). Il5, shown to have atheroprotective properties [36] , and the anti-fibrotic Il10 were significantly decreased in FGF23-treated cardiac myocytes ( Figure 5E ).
FGF23 is stimulated by the RAAS components and promotes cardiac hypertrophy of myocytes
Expressed by cardiac myocytes, FGF23 is involved in the induction of fibrotic responses in cardiac myocytes and secretion of pro-fibrotic factors, which may act on fibroblasts in a paracrine manner. Among integrins related to the NFAT signaling pathway and cardiac hypertrophy, Itgb1 and Igb5 were stimulated by FGF23 in cardiac myocytes (Supplementary data, Table  S6 ). As described for FGF2 [37] , we next wanted to determine whether FGF23 expression is induced in cardiac myocytes via fibrotic-related factors like TGF-b and/or predominant components of the RAAS to mediate pro-hypertrophic effects. Therefore NRVMs were treated with recombinant FGF23, AngII, aldosterone and TGF-b, respectively. Phenylephrine (PE) served as a positive control for the induction of pathological cardiac myocyte hypertrophy. Fgf23 mRNA expression was significantly upregulated by AngII and aldosterone, suggesting that activation of the RAAS leads to the induction of FGF23 in cardiac myocytes ( Figure 6A ). Interestingly, Fgf23 gene expression was not affected by TGF-b, PE or itself. The expression of the pro-hypertrophic genes brain natriuretic peptide (BNP), atrial natriuretic peptide (ANP) and cardiac beta-myosin heavy chain (bMHC), known to be involved in pathological cardiac hypertrophy and remodeling, was significantly induced by FGF23, AngII, aldosterone, TGF-b and PE treatment, suggesting that all these factors are pro-hypertrophic in cardiac myocytes ( Figure 6B-D) .
D I S C U S S I O N
Comparative analysis of fibrosis-related gene expression profiling in human myocardial tissue of patients with end-stage CKD presenting with elevated circulating and cardiac levels of FGF23 that associate with LVH [15, 17, 19] , along with the investigation of pro-fibrotic gene transcriptions in FGF23-stimulated cardiac fibroblasts and myocytes in vitro, revealed that FGF23 impacts on pathologic cardiac remodeling processes via stimulation of a pro-fibrotic crosstalk between cardiac myocytes and fibroblast. Our data indicate that AngII and aldosterone as active RAAS components strongly induce FGF23 in NRVMs and stimulation with FGF23 enhances the expression of AGT in both cardiac myocytes and fibroblasts. Expressed and secreted by cardiac myocytes, FGF23 directly stimulates profibrotic factors in myocytes and induces proliferation, migration and fibrosis-related pathways in fibroblasts in a paracrine manner; while acting on cardiac myocytes, FGF23 induces prohypertrophic genes and thereby promotes cardiac hypertrophy in an autocrine/paracrine fashion.
Cardiac fibrosis was highly prevalent in patients on dialysis treatment but less frequently noted in those with a functioning Mean 6 SD; **P < 0.01, ***P < 0.001 compared with vehicle-stimulated NRCFs in one-way analysis of variance followed by Bonferroni post hoc test; n ¼ 4 independent isolations of NRCFs. (B) Single-cell migration assays using NRCFs treated with vehicle, FGF23 and TGF-b. Shown are representative bright field microscopy images after 0 and 48 h, respectively, using original magnification of 20Â. (C) Quantification of FGF23 and TGF-b-stimulated migration of isolated cardiac fibroblasts in a time-depended manner. Mean 6 SD; *P < 0.05, ***P < 0.001 compared with respective vehicle-treated control cells in Student t-test; n ¼ 5-6 assays from three independent isolations of NRCFs. and Lox mRNA induction, while COL3A1 remained unaffected upon FGF23 treatment when compared with vehicle-stimulated cultured cardiac myocytes. Mean 6 SEM; *P < 0.05 in Student t-test; n ¼ 4 independent isolations of NRVMs. ns, not significant. (B) Ctgf and endothelin 1 (Edn1) were consistently upregulated by FGF23 treatment in NRVMs. Mean 6 SEM; *P < 0.05, ****P < 0.0001 in Student t-test; n ¼ 4 independent isolations of NRVMs. (C) Stimulation of NRVMs with FGF23 significantly induced the expression of extracellular matrix remodeling genes Plg, a1 Serpina1 and Serpine1 as well as Mmp9 when compared with vehicle-treated isolated cardiac myocytes. The mRNA levels of Mmp3 and Mmp8 were significantly suppressed by FGF23 stimulation of NRVMs. Mean 6 SEM; *P < 0.05, **P < 0.01, ****P < 0.0001 in Student t-test, respectively; n ¼ 4 independent isolations of NRVMs. (D) Although Tgfb1 and Tgfbr1 and Tgfbr2 mRNA levels were unchanged upon treatment of NRVMs with FGF23, latent Ltbp1 and Thbs1 gene expression was significantly induced, while Dcn was inhibited by FGF23 in NRVMs when compared with vehicle-stimulated controls. Mean 6 SEM; *P < 0.05, **P < 0.01, ****P < 0.0001 in Student t-test, respectively; n ¼ 4 independent isolations of NRVMs. ns, not significant. (E) Except for Il13, pro-inflammatory genes IL13 receptor subunit a2 (Il13ra2), Ccl11 and Tnf were significantly stimulated upon FGF23 treatment in NRVMs. FGF23 treatment significantly downregulated the mRNA expression of anti-inflammatory interleukins Il5 and Il10 in NRVMs when compared with vehicle-stimulated cardiac myocytes in vitro. Mean6 SEM; *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 in Student t-test, respectively; n ¼ 4 independent isolations of NRVMs. ns, not significant. White dots, vehicle-treated NRVMs; gray dots, FGF23-stimulated NRVMs.
renal transplant, which is well in line with previous reports [16] . The degree of cardiac fibrosis was strongly associated with dialysis vintage and klotho deficiency, and both factors together explained 84% of the overall variability of cardiac fibrosis in our patient cohort. Although FGF23 is regarded as an important cardiovascular risk factor in CKD patients [38] , no significant correlation between enhanced cardiac FGF23 expression and the degree of interstitial cardiac fibrosis was noted in the present study.
Multiple uremia-associated factors are known to be involved in the activation of fibroblasts, such as volume overload, sympathetic overactivity, oxidative stress, high phosphate and PTH levels, activation of the RAAS, klotho deficiency, inflammation and abnormal bone and mineral metabolism [1, 18] , but the precise underlying pathogenesis of uremic cardiomyopathy is still poorly understood. Among those factors, induction of AGT and soluble klotho deficiency in myocardial tissue of dialysis patients were independently associated with cardiac fibrosis. The importance of klotho in the progression of CVD is found in recent studies showing that klotho ameliorates indoxyl sulfate-induced myocardial hypertrophy in vivo [39] and that soluble klotho produced from alternative splicing suppresses myofibroblast proliferation and collagen synthesis in cultured mouse cardiac fibroblasts [40] . Furthermore, klotho negatively correlates with relative heart weight and cardiac fibrosis in mice and attenuates AngII-and TGF-b1-mediated induction of CTGF and collagen I in cardiac fibroblasts, without affecting Smad2/3 activation [18] . In cultured cardiac myocytes, soluble klotho inhibits AngII-and TGF-b1-induced hypertrophy by directly suppressing Smad2/3 phosphorylation in vitro [18] , suggesting different signaling pathways between cardiac fibroblasts and myocytes.
In the present study, AGT as a precursor of AngII, TGF-b1 and its TGF-b receptor/Smad complexes, CTGF as well as the accumulation of the fibrillar collagens I and III in myocardial tissue were all increased in CKD patients on dialysis who present with high cardiac FGF23 levels and klotho deficiency. The latter negatively correlates with TGF-b expression and its related pathway. The induction of cardiac FGF23 and reduced klotho, which was detected by immunohistochemical staining of myocardial tissue sections, strongly associate with LVH in our CKD cohort [17] and mice with higher FGF23 and lower klotho levels present more severe cardiac hypertrophy and fibrosis [18] . Klotho was neither expressed in cardiac myocytes nor in fibroblasts, suggesting that FGF23 excess promotes pathologic cardiac remodeling independent of klotho. In contrast, klotho is expressed and secreted by vascular endothelial cells in vitro and ameliorates FGF23-mediated oxidative stress via induction of nitric oxide synthesis and stimulation of antioxidant enzymes superoxide dismutase 2 and catalase to degrade reactive oxygen species [41] . Thus FGF23 promotes oxidative stress and endothelial cell dysfunction and may Stimulation with TGF-b, PE as a positive control for cardiac hypertrophy or recombinant FGF23 protein did not affect cardiac Fgf23 expression levels in NRVMs. Mean 6 SD; **P < 0.01, ****P < 0.0001 in Student t-test, respectively; n ¼ 6 independent isolations of NRVMs. (B) Quantitative real-time PCR analysis showed in induction of pro-hypertrophic gene transcription of BNP and (C) ANP by FGF23, AngII, Aldos., TGF-b and PE, respectively, when compared with vehicle-treated NRVMs. Mean 6 SD; **P < 0.01, ***P < 0.001, ****P < 0.0001 in Student t-test, respectively; n ¼ 6 independent isolation of NRVMs. (D) Quantification of cardiac bMHC mRNA expression by quantitative real-time PCR as a marker of pathological cardiac remodeling revealed significant induction upon stimulation of NRVMs with FGF23, AngII, Aldos., TGF-b, and PE, respectively. Mean 6 SD; ***P < 0.001, ****P < 0.0001 in Student t-test, respectively; n ¼ 6 independent isolations of NRVMs. White dots, vehicle-treated NRVMs; gray dots, FGF23-stimulated NRVMs; dark gray dots, all other stimulations in NRVMs.
thereby further impact on the progression of cardiovascular diseases in states of klotho deficiency.
Multiple factors are involved in the progression of cardiovascular disease in CKD patients, with the most important being activation of the RAAS. Interestingly, an activated RAAS stimulates FGF23 synthesis in bone [29, 42] and thereby promotes off-target effects of circulating FGF23 in the myocardium. In addition, FGF23 has canonical effects in the kidney, which activates the RAAS via FGFR1/klotho receptor complexes, resulting in decreased levels of soluble klotho and thereby promoting LVH [7] . Nevertheless, the RAAS is also present in the heart [43] and induces the secretion of AngII and aldosterone upon activation to trigger myocardial fibrosis and, finally, the progression of diastolic dysfunction, hypertrophy and remodeling [44] . Importantly, AngII negatively regulates klotho expression in the kidney [45] and klotho ameliorates fibrosis by targeting the RAAS, whereas loss of klotho and hyperactivation of the RAAS are common pathological findings in CKD [46] . Silencing of klotho upregulates CYP11B2, the enzyme for aldosterone synthesis [47] , and aldosterone directly induces FGF23 transcription in osteoblastic cells [48] , suggesting that enhanced cardiac fibrosis is caused by hyperaldosteronism via klotho deficiency in CKD. It has been shown that the product of ACE2 has anti-fibrotic effects on cardiac fibroblasts and prevents AngIIinduced cardiac remodeling [49] . In contrast, FGF23 is a potent inhibitor of ACE2 and thus may promote cardiac fibrosis and, consequently, cardiovascular diseases [50] . Our data demonstrate for the first time that expression of AGT, the primary RAAS component, is enhanced in the myocardial tissue of CKD patients. Furthermore, FGF23 directly induces the expression of AGT in cardiac myocytes and to a lesser extent in fibroblasts, which may affect fibrotic response. In addition, treatment with AngII and aldosterone strongly induces FGF23 expression in cardiac myocytes to stimulate the expression of pro-hypertrophic genes, suggesting that activation of cardiac RAAS and FGF23 synergistically contribute to cardiac remodeling. Whether AngII and aldosterone promote a hypertrophic response in myocytes indirectly due to the induction of FGF23 or directly via stimulation of the pathological calcineurin/NFAT signaling in cardiac myocytes remains to be elucidated. Furthermore, it remains to be shown if enhanced cardiac expression of FGF23 further mediates pathologic cardiac hypertrophy by the stimulation of pro-hypertrophic factors such as ET-1.
Wnt/b-catenin is a master regulator that controls the expression of multiple RAAS components, and klotho deficiency may result in the activation of RAAS via depression of Wnt/b-catenin, thereby promoting pressure and volume overload and hypertension contributing to LVH [51] . To the best of our knowledge, there is only one experimental study investigating the effects of FGF23 on cardiac fibrosis [52] showing an upregulation of circulating and cardiac FGF23 in mice with heart failure. The authors demonstrated an induction of b-catenin, TGF-b and collagen I and III as well as increased cardiac fibrosis in mice injected with an adeno-associated virus (AAV) carrying FGF23 followed by myocardial infarction or ischemia reperfusion. In contrast, injection of AAV-FGF23 alone does not result in enhanced b-catenin, TGF-b or collagen I and III expression levels in mice, while stimulation of cultured adult mouse cardiac fibroblasts with FGF23 increases collagen I and III on the mRNA and protein levels and inhibition of b-catenin blocks the FGF23-mediated upregulation of TGF-b and collagen I and III [52] . Thus the impact of FGF23 on b-cateninmediated induction of TGF-b and collagen synthesis remains controversial.
Our data demonstrate that the TGF-b receptor/Smad complex is activated in the myocardial tissue of dialysis patients and upon FGF23 stimulation in NRCFs. However, from the classic TGF-b/Smad target genes, only collagen III was significantly induced by FGF23 in NRCFs without affecting TGF-b1 expression, suggesting that FGF23 expressed and secreted by cardiac myocytes may promote pro-fibrotic signaling pathways in cardiac fibroblasts in a paracrine manner, promoting collagen synthesis and finally the progression of myocardial fibrosis. This is well in line with previous in vitro studies demonstrating that stimulation with FGF2 induces TGF-b1 secretion in the absence of increased TGF-b1 mRNA expression to promote cardiac fibrosis [53] . Although, our postmortem study in patients with end-stage CKD failed to show a correlation of myocardial fibrosis with enhanced cardiac FGF23 expression, our investigations in cultured cardiac fibroblasts and myocytes indicate that FGF23 induces proliferation and migration of cardiac fibroblasts and promotes a pro-fibrotic crosstalk between cardiac myocytes and fibroblasts. Moreover, the cardiac RAAS is activated in uremic cardiomyopathy, demonstrated by enhanced expression of AGT in heart tissue of our patient cohort, and most importantly, directly stimulated by FGF23 treatment in both cultured cardiac cells, which in turn strongly induces FGF23 expression in cardiac myocytes. It is tempting to speculate that circulating FGF23 levels would have correlated with the degree of cardiac fibrosis in our patient cohort, which may further support our in vitro findings. Unfortunately, due to the post-mortem study design, no plasma samples were available, which is a limitation of this study.
In conclusion, our data suggest that both activated cardiac RAAS and FGF23 synergistically promote LVH and cardiac fibrosis and may thereby contribute to the excessive cardiovascular mortality in CKD and non-CKD patients.
A U T H O R S ' C O N T R I B U T I O N S
M.L.-N. designed the study, performed the migration and proliferation assays, analysed and interpreted all data and wrote the manuscript. F.K. performed the histological and PCR array analysis, quantified the results and participated in writing the respective method. J.N. performed and quantified experiments regarding the cardiac myocytes. B.R. established the cardiac cell cultures, provided intellectual content of critical importance to the study design and revised the manuscript. B.S. analysed the migration assay and participated in writing the respective method. M.K. collected and provided the human myocardial autopsy samples, provided intellectual content to the human study and revised the manuscript. J.H. took part in the conception of functional in vitro assays, provided intellectual content of critical importance to the whole work described and revised the manuscript. D.H. designed the human study, provided intellectual content of critical importance to the whole work described and intensively revised the manuscript. All authors have read and approved submission of the manuscript.
A C K N O W L E D G E M E N T S
The authors thank Anna Gigina for the isolation of NRCFs and NRVMs and Dr Wolfgang H. Ziegler for microscopy support. Furthermore, we would like to thank Prof Jan U. Becker (University Hospital Cologne), Prof Andreas Erbersdobler and PD Dr Dagmar-Christiane Fischer (University Hospital Rostock), Prof Christoph Aufricht (University Children's Hospital Vienna) and Prof Tomas Seemann (University Children's Hospital Motol) for providing us with myocardial autopsy samples from CKD patients. 
S U P P L E M E N T A R Y D A T A
Supplementary data are available at ndt online.
C O N F L I C T O F I N T E R E S T S T A T E M E N T
None declared.
R E F E R E N C E S
